Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmerosOMER +3.44%26 Days Payable is 669.40 as of Jun. 2026, which is 57% below its 10-year median of 1,559.21. GuruFocus rates OMER with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 704 Biotechnology companies, Omeros ranks better than 90.48% on this metric.
Omeros's average Accounts Payable for the
three
months ended in Jun. 2026 was $5.85 Mil. Omeros's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $0.80 Mil.
Hence, Omeros's Days Payable for the
three
months ended in Jun. 2026 was 669.40.
The historical rank and industry rank for Omeros's Days Payable or its related term are showing as below:
OMER'
s Days Payable Range Over the Past 10 Years
Min: 1156.39 Med: 1559.21 Max: 4623.81
Current: 1992.82
During the past 13 years, Omeros's highest Days Payable was 4623.81. The lowest was 1156.39. And the median was 1559.21.
OMER's Days Payable is ranked better than 90.48% of 704
companies
in the Biotechnology industry
Industry Median: 110.01
vs OMER: 1992.82
Omeros's Days Payable
increased
from Jun. 2025 (0.00) to Jun. 2026 (669.40).
It may suggest that Omerosdelayed paying its suppliers.
The historical data trend for Omeros's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Omeros's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omeros Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Omeros's Days Payable distribution charts can be found below:
* The bar in red indicates where Omeros's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Omeros's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omeros (OMER) has a Days Payable of 669.40 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Omeros and its competitors. This is 57% below median its historical median of 1,559.21. Over the past decade, Omeros' Days Payable has ranged from 1,156.39 to 4,623.81. According to the industry distribution chart, Omeros ranks #67 out of 704 companies in the Biotechnology industry, placing it in the top 9.5%.
Is Omeros' Days Payable too high?
Omeros' current Days Payable of 669.40 is 57% below median its 10-year median of 1,559.21. Over the past 10 years, this metric has ranged from a low of 1,156.39 to a high of 4,623.81. The Biotechnology industry median Days Payable is 110.01. Omeros' value of 669.40 is 508.5% above this industry median. Based on the distribution chart, Omeros ranks #67 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Omeros has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Omeros' Days Payable compare to STTK and BBOT?
According to the Biotechnology industry distribution chart, Omeros ranks #67 out of 704 companies for Days Payable. This places Omeros in the top 10% of its industry — outperforming the majority of peers. The industry median Days Payable is 110.01. Omeros' value of 669.40 is 508.5% above this benchmark. Historically, Omeros' own Days Payable has ranged from 1,156.39 to 4,623.81 over the past decade. While the company's 10-year median is 1,559.21 vs. the industry median of 110.01, Omeros has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omeros's current Days Payable of 669.40 is 508.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Omeros and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omeros's current Days Payable is 669.40, which is 57% below median its own 10-year median of 1,559.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omeros stock overvalued right now?
Omeros (OMER) has a current Days Payable of 669.40. The current Days Payable is 669.40, which is 57% below median its 10-year median of 1,559.21 and 508.5% above the Biotechnology industry median of 110.01. Omeros' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Omeros (OMER), the current Days Payable is 669.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
26GF Score
Get the complete analysis for OMER
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OMER has been successfully added to your 
